Acquired hepatocerebral degeneration in a patient with hepatitis B and hepatitis delta virus coinfection

Abstract Acquired hepatocerebral degeneration is a neurological syndrome with typical clinical (extrapyramidal and neuropsychiatric) symptoms and brain magnetic resonance imaging findings (high T1 signal in the globus pallidus). It occurs mainly in patients with advanced liver disease, such as in patients co-infected with hepatitis B virus (HBV) and hepatitis delta virus (HDV). However, there are no reports relating HBV/HDV coinfection and acquired hepatocerebral degeneration. This report presents the case of a 49-year-old woman with characteristics of acquired hepatocerebral degeneration and liver cirrhosis due to HBV/HDV coinfection, and presents the main theories of the physiopathology of this condition.

Seroprevalence of hepatitis B virus and its co-infection with hepatitis D virus and hepatitis C virus in Iranian adult population.

CONTEXT: Hepatitis B virus (HBV) infection is one of the most prevalent public health problems worldwide (especially in developing countries). AIMS: This study was carried out to determine the seroprevalence of HBV and its co-infection with hepatitis D (HDV) and C (HCV) viruses in the northeastern part of Iran. SETTING AND DESIGN: A population-based cross-sectional study in Iran. MATERIALS AND METHODS: As many as 1,850 subjects were explored for HBsAg. Anti-HDV and anti-HCV antibodies were assessed in HBsAg-positive cases. STATISTICAL ANALYSIS USED: Proportions were compared by Chi-square and Fisher's exact tests. RESULTS: The mean age of subjects was 43.86 +/- 11.2 years. The age- and sex-standardized prevalence for HBsAg positivity was 9.7%. It was higher in males than in females (OR: 1.28; 95% CI: 0.9-1.7). The risk of infection in singles was significantly higher than in married cases (OR: 2.13). Eight (5.8%) of HBsAg-positive cases were infected with HDV and 17 (12.3%) were positive for anti-HCV antibody. CONCLUSION: This study demonstrates that the prevalence of HBsAg seropositivity in Golestan province of Iran is higher than the levels reported by WHO and previous studies from Iran. It is very important, especially for health providers and policy makers, to recognize the risk factors of HBV infection and its co-infection with HDV and HCV in this area and design effective preventive programs.

Low prevalence of hepatitis B virus, hepatitis D virus and hepatitis C virus among patients with human immunodeficiency virus or acquired immunodeficiency syndrome in the Brazilian Amazon basin

Comorbidities in human immunodeficiency virus infection are of great interest due to their association with unfavorable outcomes and failure of antiretroviral therapy. This study evaluated the prevalence of coinfection by human immunodeficiency virus and viral hepatitis in an endemic area for hepatitis B in the Western Amazon basin. Serological markers for hepatitis B virus, hepatitis C virus and hepatitis D virus were tested in a consecutive sample of all patients referred for treatment of human immunodeficiency virus or acquired immunodeficiency syndrome. The variables sex, age, origin and exposure category were obtained from medical records and from the sexually transmitted diseases and acquired immunodeficiency syndrome surveillance database. Among 704 subjects, the prevalence of chronic hepatitis B carriage was 6.4 percent and past infection 40.2 percent. The presence of hepatitis B was associated with birth in hyperendemic areas of the Amazon basin, male sex and illegal drug use. The overall prevalence of hepatitis C was 5 percent and was associated with illegal drug use. The prevalence of hepatitis B and C among human immunodeficiency virus or acquired immunodeficiency syndrome patients in the Western Amazon basin was lower than seen elsewhere and is probably associated with the local epidemiology of these viruses and the degree of overlap of their shared risk factors. An opportunity presents itself to evaluate the prevention of hepatitis C through harm reduction policies and hepatitis B through vaccination programs among human immunodeficiency virus or acquired immunodeficiency syndrome patients.

Co-morbidades na infecção pelo vírus da imunodeficiência humana são de grande interesse devido à associação com desfechos desfavoráveis e falhas na terapia anti-retroviral. Este estudo avalia a prevalência de co-infecção entre o vírus da imunodeficiência humana e hepatites virais, em uma área endêmica de hepatite B, na Amazônia Ocidental. Marcadores sorológicos para o Vírus da hepatite B, Vírus da hepatite C e vírus da hepatite D foram testados em uma amostra de pacientes referenciado para o tratamento em ambulatório para pacientes com infecção pelo vírus da imunodeficiência humana ou síndrome da imunodeficiência adquirida. As variáveis: sexo, idade, origem e categoria de exposição, foram obtidas dos prontuários médicos e do banco de dados da Coordenação Estadual de Doenças sexualmente transmissíveis. Entre os 704 indivíduos incluídos, a prevalência de portador crônico do vírus da hepatite B foi 6,4 por cento e de infecção passada 40,2 por cento. O vírus da hepatite B esteve associado com o local de nascimento em áreas hiperendêmicas da Amazônia, sexo masculino e uso de drogas ilícitas. A prevalência de hepatite C foi 5 por cento, estando associada com uso de drogas ilícitas. A prevalência dos vírus da hepatite B e C, entre indivíduos vivendo com o vírus da imunodeficiência humana e síndrome da imunodeficiência adquirida, na Amazônia ocidental, foi mais baixa que as observadas em estudos com populações de outras regiões. Provavelmente, estes resultados estão associados à epidemiologia local destes vírus, e ao grau de superposição dos fatores de risco associados à infecção na população estudada. O estudo apresenta oportunidade de avaliar a prevenção da hepatite C e B, através de medidas de redução de danos e programa de vacinação em indivíduos vivendo com vírus da imunodeficiência humana e síndrome da imunodeficiência adquirida.

Seroprevalence of hepatitis D virus in patients with hepatitis B virus-related liver diseases.

BACKGROUND AND OBJECTIVE: Several reports indicated a declining trend in the occurrence of hepatitis D virus (HDV) infection in some geographical areas. However, no study has been conducted in India to evaluate whether a similar epidemiological change is occurring in this part of the world. The present study was undertaken to evaluate the seroprevalence of HDV in patients with hepatitis B virus (HBV) related liver diseases attending a Government hospital in New Delhi, and to assess any change in its epidemiology by comparing the results with seroprevalence figures reported in the past. METHODS: A total of 123 patients with HBV-related liver diseases comprising 32 cases of acute viral hepatitis (AVH), 5 of fulminant hepatic failure (FHF), 37 of chronic hepatitis (CH), 46 of cirrhosis and 3 of hepatocellular carcinoma (HCC). All patients were evaluated for the presence of delta antibodies using commercially available ELISA kits. Both IgM and IgG anti-delta assays were performed to differentiate between active and convalescent infection. RESULTS: The mean age of the patients was 35.6 +/- 3.3 yr with a male : female ratio of 11:5. Of the 123 patients, serological evidence of delta virus infection was seen in 13 subjects (10.6%); 9 (7.3%) had evidence of past infection (IgG positive, IgM negative) and the remaining 4 (3.3%) recent infection (IgM anti-delta antibody positive). Evidence of HDV infection in acute viral hepatitis, fulminant hepatitis, chronic hepatitis, cirrhosis and hepatocellular carcinoma groups was found in 3.1, 20, 8.1, 15.2 and 33.3 patients, respectively. INTERPRETATION AND CONCLUSION: Our results suggest that delta infection may not be very common in Indian patients with HBV-related liver diseases. It is also possible that HDV epidemiology in this part of the world may be undergoing a transition towards decreasing prevalence.

Hepatopatias fulminantes/febres hemorrágicas na Amazônia: revisão histórica, padrões de lesão hepática e diagnóstico etiológico / Fulminant hepatic failure/hemorrhagic fevers in Amazon Basin: historical review, hepatic damage patterns and etiological diagnosis

Esta análise morfológica e imuno-histoquímica de hepatopatias fulminantes da Amazônia incluindo a série histórica original de Hepatite de Lábrea (HL) e casos de Febre Amarela (FA) concentrou-se em padrões de lesão . Mostraram-se características da FA: morte celular por apoptose medio-zonal, balonização hepatocelular, elevado índice de proliferação celular avaliado pelo PCNA e flebite portal. Os casos de HL mostraram extensa necrose hepatocelular lítica, células “em mórula”, regeneração hepatocelular com multinucleações e transformação pseudo-acinar, flebite portal e centro-lobular, com extinção parenquimatosa, depósitos portais de fibras elásticas e colágeno tipo I e depósitos lobulares de colágeno III / This morphologic and immunohistochemical analysis of fulminant hepatic failure from Amazon Basin, including the original historical series of Labrea Hepatitis (LH) and of Yellow fever (YF) cases was concentrated on lesion patterns. Midzonal apoptotic cellular death, hepatocellular ballooning degeneration, high cellular proliferation index assessed by PCNA and portal phlebitis were shown to be characteristics of YF. LH cases showed extensive lytic hepatocellular necrosis, “morula cells”, hepatocellular regeneration with multinucleation and pseudo-acinar transformation, portal and hepatic vein phlebitis, with parenchymal extinction, portal elastic fibers and type I collagen fibers and lobular type III collagen fiber deposition...

The Prevalence and Clinical Characteristics of Hepatitis-delta Infection in Korea / 대한간학회지

BACKGROUND/AIMS: The prevalence of hepatitis delta virus (HDV) infection has been estimated as being approximately 5% among global HBsAg carriers. The anti-delta positive rate in Koreans had been reported as being 0.85% in 1985. While the prevalence of HBV has been decreased from nearly 10% to 5% during the past twenty years, there have been no more studies on the anti-delta prevalence in Koreans. The aim of this study was to estimate the anti-delta prevalence in Koreans and to study the clinical characteristics of anti-delta positive patients in a single center. METHODS: Serum anti-delta was measured in one hundred ninety four HBsAg-positive patients who were admitted to our hospital from February 2003 to August 2003. We checked the genotypes of the HBV in the anti-delta positive patients. The clinical features of the anti-delta positive patients were compared to those clinical features of the anti-delta negative patients from the aspect of age, gender, mode of transmission, the positivity of HBeAg and serum HBV DNA. RESULTS: Serum anti-delta was positive in seven patients among the 194 subjects, giving a 3.6% positive rate. Among these seven patients, six had hepatocellular carcinoma (HCC) and the other one had cholangiocarcinoma. All of the anti-delta positive patients had the C genotype of HBV. The anti-delta positive patients showed significantly suppressed HBV DNA replication compared to the anti-delta negative patients. CONCLUSIONS: In Koreans, anti-delta was positive mainly in HCC patients with an approximate prevalence of 4%, and this rate has not changed much for the past twenty years. HBV DNA replication was suppressed by HDV infection.

Prevalencia de afección hepática, alcoholismo, hepatitis B, C y HIV en pacientes con antecedentes de consum / Prevalence of hepatic involvement, alcoholism, hepatis B, C and HIV in patients with background history of drug use

Drug addicts frequently have liver diseases for different reasons: alcohol abuse, the drugs themselves, but more often hepatitis B and C infections. AIDS is common in this population as well and could also affect the liver directly or in the form of hepatocellular or biliary damage. We conducted this study to determine the prevalence of liver diseases, alcoholism, hepatitis B and C infections, and HIV positivity in this population. We studied a cohort of 137 persons, all with a history of drug abuse, and investigated the quantity of alcohol intake, the kind of drug used, and he routes of drug administration. RESULTS: We found liver disease in 33.6%. The prevalence of alcoholism was 65.4%, of HCV 67.3%, and of HBV 17.3%. HDV was undetectable, whereas we found HIV at a frequency of 17.3%. HCV RNA was detected in 85.4% of HCV. The drug most often used was cocaine at 90.4%, followed by marihuana at 88.3%; LSD use occurred in 17.5%. We found parenteral drug use in 43.1%. We performed 22 liver biopsies, 21 associated with HCV, and detected histological changes consistent with chronic hepatitis in 17, with cirrhosis in 4, and with hepatocellularcarcinoma in 1.

Prevalence of hepatitis C virus among patients with liver disease in the Republic of Yemen

We investigated 143 patients with various classes of liver disease and 120 healthy subjects for serological markers of hepatitis C and B viruses. We found a prevalence rate of 37.1% of anti-HCV markers in patients with liver disease [cases], and 4.2% and in the control group. HBsAg was detected in 33.6% of cases and 13.3% of the controls. Anti-HCV and HBsAg were detected in 7.7% of cases but were not detected in the controls. Anti-HCV, HBsAg, anti-HBe and anti-HDV were detected in three patients. Serum protein electrophoresis results showed elevated gammaglobulin and low albumin in patients positive for anti-HCV who had liver disease

Hepatitis D infectivity profile among hepatitis B infected hospitalised patients in Calcutta.

450 hospitalised cases of hepatic and non hepatic disorders and 100 normal individuals were examined for serum Hepatitis B Surface antigen and Delta Virus antigen by ELISA to find out its association with different clinical disorders. 105 patients (23.3%) and 2 control (2%) were positive for HBsAG. 60 cases with jaundice (26%) were HBsAg positive. 65% of HBsAg positive jaundiced patients had serum bilirubin level more than 2 mg per dl with a mean SGPT level of 488 iu/L. Only two cases were positive for HDV antigen among 60 HBsAg positive jaundice patients indicating a lower rate of prevalence of infection (3.3%). 62 (59%) out of 105 HBsAg positive cases did not show any history of blood transfusion or surgical interference indicating a positive HBV transmission through needle prick during investigative procedures.

A prospective study of delta infection in fulminant hepatic failure.

Thirty one patients of HBV related Fulminant Hepatic Failure (FHF) were studied for the presence of delta infection and subsequently the clinical features, course and outcome of the delta infected cases was compared with those of delta uninfected cases. Out of 31 patients studied, 11 patients (35.8%) were reactive for anti-delta antibodies. There was no significant difference in age in delta reactive and non-reactive group. Hepatic encephalopathy was seen in all of the patients. The mean SGOT and SGPT were 378 +/- 88.74 U and 454 +/- 70.44 U respectively in anti-delta reactive group as compared to 239 +/- 74.94 U and 274.1 +/- 100.34 U respectively in anti-delta non reactive group (p < 0.05). During follow up, 10/11 patients (91%) died in anti-delta reactive group as compared to 13/20 patients (65%) in anti-delta non reactive group. So this study suggests that delta virus infection is quite common in India and it lead to excerbation of illness and carries a relatively poor prognosis for FHF.

Rol de los virus de hepatitis B y Delta en la etiología del hepatocarcinoma y otras crónicas / Etiological rol of B and Delta virus in hepatocarcinoma and other chronic liver disorders

Se estudiaron de forma prospectiva 23 pacientes con cuadros hepáticos crónicos hospitalizados en los Servicios de Medicina en un hospital de referencia de zonas de alta endemicidad de Hepatitis B y Delta ( Puerto maldonado, Abancay y La Convención) como es el Hospital Regional MINSA del Cusco, durante el período de un año. El diagnóstico de los cuadros hepáticos crónicos fue histopatológico por biopsia hepática en 16 de los pacientes, en el resto clínico-laboratorial, debido a que la biopsia hepática estaba contraindicada; la determinación de la infección viral se realizó mediante el dosaje de los siguientes marcadores serológicos: antígeno de superficie (AgHBs), anticuerpo anti-antígeno core IgG (Anti-HBc IgG) y antidelta.Seencontró que el 34.8 por ciento fueron antígeno de superficie positivos y el 65.2 por ciento anticuerpo anti-antígeno core IgG positivos; el 20 por ciento de estos últimos fueron además positivos a anticuerpo anti-antígeno delta

Hepatitis viral delta

The etiologic agent of this severe form of hepatitis was identified by Rizzetto et al in Italy in 1977. The Delta virus resembles satellite viruses of plants which can not replicate without another specific virus. In this particular case hepatitis B virus is the helper agent. Clinically this form of hepatitis is characterized by two presentations: coinfeccion, which means simultaneous infection of a host with hepatitis B virus and hepatitis D virus. This variety of hepatitis can present with two distinct peaks of transaminases and usually resolves completely in most of the cases, however 0-4 percent can evolve to chronic hepatitis and 25 percent of the cases of fulminant hepatitis are due to this viral association. The diagnosis can be established demonstrating anti-HDV IgM or HDV-RNA or HDV antigen in the serum. In essence coinfection makers acute hepatic failure more common and the mortality is significantly higher than hepatitis B infections by itself. The second type of clinical presentation is superinfection, which means infection with the Delta virus of a patient previously infected with the hepatitis B virus (healthy carrier). Initially the patient develop a typical acute viral hepatitis in 50-70 percent of the cases, and 30-50 percent can have asymptomatic infection. The real problem with this presentation is that 20-90 percent of the cases evolved to chronicity: chronic active hepatitis and cirrhosis. The diagnosis can be made demonstrating anti-HDB IgM and anti-HDV IfG, although this last one is usually transitory. A liver biopsy can show HDV RNA or HDV antigen using special immunostainings...

Prevalence of delta virus infection in high risk population and hepatitis B virus related liver diseases.

Two hundred and fifty four high risk persons or patients with hepatitis B virus related liver disease (209 men, 45 women; age range 1-78 years) were tested for anti-delta antibody and IgM anti-HBc to determine the prevalence of delta agent coinfection and superinfection. The prevalence of delta infection was as follows: acute viral hepatitis 23/148 (16%) and chronic liver disease 17/92 (19%), and asymptomatic HBsAg carriers 1/6 (17%). In the high risk population, the delta antibody prevalence was as follows: multiple transfusion recipients 3/8 (38%), patients with chronic renal failure 1/5 (20%) and medical professionals 2/7 (29%). Of 44 patients (34 men, 10 women; age 3-63 years) with delta infection, 26 (59%) had coinfection and 18 (41%) had superinfection. Six patients with anti-delta antibody had received blood transfusion(s) and six others gave history of parenteral exposure.

Delta virus infection and severe hepatitis [reported epidemics in Sind]

Large outbreaks of acute hepatitis are unusual in the developing world. Recently large epidemics have been reported in various parts of Asia and have been attributed to hepatitis non A-non B, presumably spread through water. We report here three epidemics of severe hepatitis that resulted from spread of delta agent in three different places in Sind province. The report implicates the delta agent as a possible cause of epidemic hepatitis and sheds further light on the natural course of delta virus infection

Ausencia de infección por virus Delta en sujetos masculinos de alto riesgo infectados por virus B y virus de la inmunodeficiencia humana / Absence of delta agent infection in high risk male subjects infected with B virus and human immunodeficiency virus

Contactos positivos para VD fueron investigados en un grupo de 50 sujetos masculinos, 48 homosexuales y 2 heterosexuales con antecedente de drogadicción intravenosa. Ninguno demostró presencia de anticuerpos anti-VD, mientras que el 98% y el 50% del grupo total presentó reactividad comprobada para VIH y VHB respectivamente. Es más, 19 sujetos que notificaron un número igual o superior a 5 parejas sexuales por año, presentaban uno o más marcadores del VHB, hallazgo sólo observado en 6 sujetos de 31 que notificaron menos de 5 parejas por año (p < 0.001). La no evidencia de contactos positivos para VD sugieren que el comportamiento epidemiológico de este virus es menos o no dependiente de a condición sexual de la población expuesta

High prevalence of delta virus infection in Thai intravenous drug abusers.

The prevalence of antibodies to delta virus (anti-delta) in the selected groups of hepatitis B surface antigenemia population was investigated. The subjects were 84 intravenous drug abusers; 20 chronic hepatitis, 12 cirrhosis, 6 primary hepatocellular carcinoma and 46 asymptomatic healthy carriers. Anti-delta was detected in 65.48% of intravenous drug abusers, 11.11% of chronic active hepatitis and 8.33% of cirrhosis cases. None of asymptomatic carriers had anti-delta. In addition, 51 acute icteric hepatitis B patients who were positive for HBs Ag and 20 IV drug abusers positive for anti-HBc only (HBsAg and anti-HBs negative) were negative for anti-delta.